 Cyclohexanes
"Cyclohexanes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Six-carbon alicyclic hydrocarbons.
| Descriptor ID |
D003510
|
| MeSH Number(s) |
D02.455.426.392.368.367
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cyclohexanes".
Below are MeSH descriptors whose meaning is more specific than "Cyclohexanes".
This graph shows the total number of publications written about "Cyclohexanes" by people in this website by year, and whether "Cyclohexanes" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 2 | 2 | | 2001 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 | | 2010 | 1 | 1 | 2 | | 2013 | 2 | 0 | 2 | | 2015 | 0 | 1 | 1 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cyclohexanes" by people in Profiles.
-
Rosebush JC, Best BM, Chadwick EG, Butler K, Moye J, Smith E, Bradford S, Reding CA, Mathiba SR, Hanley S, Aziz M, Homans J, Acosta EP, Murtaugh W, Vourvahis M, Mcfadyen L, Hayward K, Mirochnick M, Samson P. Pharmacokinetics and safety of maraviroc in neonates. AIDS. 2021 03 01; 35(3):419-427.
-
Frankenberger C, Rabe D, Bainer R, Sankarasharma D, Chada K, Krausz T, Gilad Y, Becker L, Rosner MR. Metastasis Suppressors Regulate the Tumor Microenvironment by Blocking Recruitment of Prometastatic Tumor-Associated Macrophages. Cancer Res. 2015 Oct 01; 75(19):4063-73.
-
Preiss D, Giles TD, Thomas LE, Sun JL, Haffner SM, Holman RR, Standl E, Mazzone T, Rutten GE, Tognoni G, Chiang FT, McMurray JJ, Califf RM. Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. Stroke. 2013 Sep; 44(9):2590-3.
-
Wong YW, Thomas L, Sun JL, McMurray JJ, Krum H, Hernandez AF, Rutten GE, Leiter LA, Standl E, Haffner SM, Mazzone T, Martinez FA, Tognoni G, Giles T, Califf RM. Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study. Circ Heart Fail. 2013 Mar; 6(2):203-10.
-
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010 Apr 22; 362(16):1477-90.
-
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010 Apr 22; 362(16):1463-76.
-
Kapoor JR. Postprandial hyperglycemia: are all sulfonylureas created equal? Am J Cardiol. 2008 Feb 15; 101(4):554-5.
-
Huang J, Frischer JS, New T, Kim ES, Serur A, Lee A, Kadenhe-Chiwishe A, Pollyea DA, Yokoi A, Holash J, Yancopoulos GD, Kandel JJ, Yamashiro DJ. TNP-470 promotes initial vascular sprouting in xenograft tumors. . 2004 Mar; 3(3):335-43.
-
Katzenstein HM, Salwen HR, Nguyen NN, Meitar D, Cohn SL. Antiangiogenic therapy inhibits human neuroblastoma growth. Med Pediatr Oncol. 2001 Jan; 36(1):190-3.
-
Katzenstein HM, Rademaker AW, Senger C, Salwen HR, Nguyen NN, Thorner PS, Litsas L, Cohn SL. Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. Clin Cancer Res. 1999 Dec; 5(12):4273-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|